Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 16/20 | 0.68 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | CCKBR | P32239 | 1/20 | 0.66 |
| ▸ | GLP1R | P43220 | 1/20 | 0.66 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30773852 | 0.98 | NPBWR1 (0.69) | NPBWR1RXFP1CCKBRGLP1RPTH1R | |
| SCHEMBL29669569 | 0.98 | NPBWR1 (0.66) | NPBWR1RXFP1CCKBRGLP1RPTH1R | |
| SCHEMBL29669608 | 0.97 | NPBWR1 (0.65) | NPBWR1RXFP1CCKBRGLP1RPTH1R | |
| SCHEMBL29669637 | 0.96 | NPBWR1 (0.71) | NPBWR1 | |
| SCHEMBL30773849 | 0.95 | NPBWR1 (0.67) | NPBWR1RXFP1CCKBRGLP1RPTH1R | |
| SCHEMBL29669568 | 0.95 | NPBWR1 (0.66) | NPBWR1RXFP1CCKBRGLP1RPTH1R | |
| SCHEMBL29669735 | 0.94 | RXFP1 (0.64) | NPBWR1RXFP1CCKBRGLP1RPTH1R | |
| SCHEMBL29669730 | 0.92 | NPBWR1 (0.64) | NPBWR1RXFP1CCKBRGLP1RPTH1R | |
| SCHEMBL31182496 | 0.91 | GLP1R (0.68) | RXFP1CCKBRGLP1RPTH1RIL23R | |
| SCHEMBL30130562 | 0.88 | KISS1R (0.62) | NPBWR1GLP1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114641486-B | For reducing CB1Peptide compounds for side effects of receptor agonists | 庞培法布拉大学 | 2025-04-01 | — | — | CN | claimed |
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | UNIVERSITAT DE BARCELONA (ES) | 2025-11-04 | — | — | US | disclosed |
| CN-114641486-B | For reducing CB1Peptide compounds for side effects of receptor agonists | 庞培法布拉大学 | 2025-04-01 | — | — | CN | disclosed |
| US-20240059737-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | UNIVERSITAT POMPEU FABRA (ES) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459973-B2 | Peptide compounds for reducing side effects of CB1 receptor agonists | CNR2, CNR1, OPRD1 | NPBWR1 51/4885RXFP1 53/4885CCKBR 12/4885 |
| US-20240059737-A1 | PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS | CNR2, CNR1, OPRD1 | NPBWR1 53/4885RXFP1 49/4885CCKBR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.